Okko-Sakari Kääriäinen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Okko-Sakari Kääriäinen has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Eliisa Löyttyniemi
Department of Biostatistics, University of Turku, Turku, Finland
2 shared publications - Päivi Auvinen
Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland; Department of Oncology, Kuopio University Hospital, the Wellbeing services county of North Savo, Finland
2 shared publications - Anni Borkvel
North Estonia Medical Centre, J. Sütiste tee 19, 13419 Tallinn, Estonia
1 shared publication - Anniina Hyväkkä
Department of Oncology and FICAN West Cancer Center, University of Turku and Turku University Hospital, Turku, Finland
1 shared publication - Annika Auranen
Department of Obstetrics and Gynecology Tampere University Hospital Tampere Finland
1 shared publication Antti Rannikko
Research Programme in Systems Oncology and Department of Urology, University of Helsinki and University Hospital, Helsinki, Finland
1 shared publication
Latest Publications
- Open Access
- 11 November 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1515-1522
Real-world outcomes of 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: the KuPSMALu trial in Eastern Finland
Background and purpose: Radioligand therapy targeting prostate-specific membrane antigen (PSMA) with lutetium-177 PSMA (¹⁷⁷Lu-PSMA) compounds has emerged as an effective treatment for metastatic castration-resistant prostate cancer (mCRPC). The KuPSMALu trial evaluated the real-world efficacy and safety of in-house produced ¹⁷⁷Lu-PSMA imaging & therapy (I&T) for mCRPC patients in a public healthcare setting and assessed whether selection based on ¹⁸F-PSMA-PET and contrast-enhanced CT – without FDG-PET – provides favourable oncological outcomes. Patients/material and methods: This prospective, single-centre observational study included 40 patients with PSMA-positive mCRPC who had progressed after chemotherapy and at least one androgen receptor pathway inhibitor. Patients received 3–6 cycles of ¹⁷⁷Lu-PSMA-I&T at 6–8-week intervals. Imaging, blood-based markers and patient-reported outcomes were collected longitudinally. Dosimetry, adverse events (AEs) and quality-of-life metrics were systematically assessed. Results: The median overall survival (mOS) was 16.0 months. ECOG 0–1 patients had significantly longer mOS than ECOG 2 patients (20.0 vs. 4.7 months, p < 0.01). A PSA decrease ≥ 50% was observed in 40% of patients and correlated with improved mOS (23.7 vs. 9.1 months, p < 0.01). PSA doubling time (dt) > 4 months predicted superior survival (23.8 vs. 12.6 months, p = 0.040). Grade ≥ 3 AEs occurred in only 12.3% of patients. Interpretation: In-house ¹⁷⁷Lu-PSMA-I&T production combined with pragmatic imaging-based patient selection provides a safe, cost-effective therapy for mCRPC in public healthcare. PSA kinetics, particularly PSA dt, are strong predictors of therapeutic benefit. The findings align with VISION and TheraP trials and highlight the feasibility of integrating radioligand therapy into routine clinical care.
- 11 November 2025
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 64, 1515-1522
Open AccessReal-world outcomes of 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: the KuPSMALu trial in Eastern Finland
Background and purpose: Radioligand therapy targeting prostate-specific membrane antigen (PSMA) with lutetium-177 PSMA (¹⁷⁷Lu-PSMA) compounds has emerged as an effective treatment for metastatic castration-resistant prostate cancer (mCRPC). The KuPSMALu trial evaluated the real-world efficacy and safety of in-house produced ¹⁷⁷Lu-PSMA imaging & therapy (I&T) for mCRPC patients in a public healthcare setting and assessed whether selection based on ¹⁸F-PSMA-PET and contrast-enhanced CT – without FDG-PET – provides favourable oncological outcomes. Patients/material and methods: This prospective, single-centre observational study included 40 patients with PSMA-positive mCRPC who had progressed after chemotherapy and at least one androgen receptor pathway inhibitor. Patients received 3–6 cycles of ¹⁷⁷Lu-PSMA-I&T at 6–8-week intervals. Imaging, blood-based markers and patient-reported outcomes were collected longitudinally. Dosimetry, adverse events (AEs) and quality-of-life metrics were systematically assessed. Results: The median overall survival (mOS) was 16.0 months. ECOG 0–1 patients had significantly longer mOS than ECOG 2 patients (20.0 vs. 4.7 months, p < 0.01). A PSA decrease ≥ 50% was observed in 40% of patients and correlated with improved mOS (23.7 vs. 9.1 months, p < 0.01). PSA doubling time (dt) > 4 months predicted superior survival (23.8 vs. 12.6 months, p = 0.040). Grade ≥ 3 AEs occurred in only 12.3% of patients. Interpretation: In-house ¹⁷⁷Lu-PSMA-I&T production combined with pragmatic imaging-based patient selection provides a safe, cost-effective therapy for mCRPC in public healthcare. PSA kinetics, particularly PSA dt, are strong predictors of therapeutic benefit. The findings align with VISION and TheraP trials and highlight the feasibility of integrating radioligand therapy into routine clinical care.
- Open Access
- 1 September 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (6) , 102427
Healthcare Resource Use and Costs of Localized Prostate Cancer Patients in Finland
- 1 September 2025
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 23 (6) , 102427
Open AccessHealthcare Resource Use and Costs of Localized Prostate Cancer Patients in Finland
- Open Access
- 23 May 2024
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 63, 395-397
A national precision cancer medicine implementation initiative for Finland
- 23 May 2024
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 63, 395-397
Open AccessA national precision cancer medicine implementation initiative for Finland
- Open Access
- 26 September 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (4) , 4064-4076
Radium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study
Background: Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in castration‐resistant prostate cancer (CRPC) with bone metastases. However, real‐world data are also needed with wider inclusion criteria.Methods: We report results of a retrospective multicenter study including all patients with metastatic CRPC treated with radium‐223 in all five university hospitals in Finland since the introduction of the treatment. We identified 160 patients who had received radium‐223 in Finland in 2014–2019.Results: The median overall survival (OS) was 13.8 months (range 0.5–57 months), and the median real‐world progression‐free survival (rwPFS) was 4.9 months (range 0.5–29.8 months). Alkaline phosphatase (ALP) values within the normal range before and during the radium‐223 treatment or the reduction of elevated ALP to normal range during treatment were associated with better OS when compared to elevated ALP values before and during treatment (p < 0.0001). High prostate‐specific antigen (PSA) level (≥100 μg/L) before radium‐223 treatment was associated with poor OS compared to low PSA level (p = 0.0001). Most patients (57%) experienced pain relief. Pain relief indicated better OS (p = 0.002). Radium‐223 treatment was well tolerated. Toxicity was mostly low grade. Only 12.5% of the patients had grade III–IV adverse events, most commonly anemia, neutropenia, leucopenia, and thrombocytopenia.Conclusion: Radium‐223 was well tolerated in routine clinical practice, and most patients achieved pain relief. Pain relief, ALP normalization, lower baseline PSA, and PSA decrease during radium‐223 treatment were prognostic for better survival. The efficacy of radium‐223 in mCRPC as estimated using OS was comparable to earlier randomized trial in this retrospective real‐world study. Our results support using radium‐223 for mCRPC patients with symptomatic bone metastases even in the era of new‐generation androgen receptor‐targeted agents.
- 26 September 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (4) , 4064-4076
Open AccessRadium‐223 dichloride treatment in metastatic castration‐resistant prostate cancer in Finland: A real‐world evidence multicenter study
Background: Radium‐233 dichloride is an alpha emitter that specifically targets bone metastases in prostate cancer. Results of a previously reported phase III randomized trial showed survival benefit for radium‐223 compared to best supportive care in castration‐resistant prostate cancer (CRPC) with bone metastases. However, real‐world data are also needed with wider inclusion criteria.Methods: We report results of a retrospective multicenter study including all patients with metastatic CRPC treated with radium‐223 in all five university hospitals in Finland since the introduction of the treatment. We identified 160 patients who had received radium‐223 in Finland in 2014–2019.Results: The median overall survival (OS) was 13.8 months (range 0.5–57 months), and the median real‐world progression‐free survival (rwPFS) was 4.9 months (range 0.5–29.8 months). Alkaline phosphatase (ALP) values within the normal range before and during the radium‐223 treatment or the reduction of elevated ALP to normal range during treatment were associated with better OS when compared to elevated ALP values before and during treatment (p < 0.0001). High prostate‐specific antigen (PSA) level (≥100 μg/L) before radium‐223 treatment was associated with poor OS compared to low PSA level (p = 0.0001). Most patients (57%) experienced pain relief. Pain relief indicated better OS (p = 0.002). Radium‐223 treatment was well tolerated. Toxicity was mostly low grade. Only 12.5% of the patients had grade III–IV adverse events, most commonly anemia, neutropenia, leucopenia, and thrombocytopenia.Conclusion: Radium‐223 was well tolerated in routine clinical practice, and most patients achieved pain relief. Pain relief, ALP normalization, lower baseline PSA, and PSA decrease during radium‐223 treatment were prognostic for better survival. The efficacy of radium‐223 in mCRPC as estimated using OS was comparable to earlier randomized trial in this retrospective real‐world study. Our results support using radium‐223 for mCRPC patients with symptomatic bone metastases even in the era of new‐generation androgen receptor‐targeted agents.
- Open Access
- 17 November 2020
- Published by MDPI AG in Diagnostics
- Vol. 10 (11) , 959
A Deep Learning-Based Automated CT Segmentation of Prostate Cancer Anatomy for Radiation Therapy Planning-A Retrospective Multicenter Study
A commercial deep learning (DL)-based automated segmentation tool (AST) for computed tomography (CT) is evaluated for accuracy and efficiency gain within prostate cancer patients. Thirty patients from six clinics were reviewed with manual- (MC), automated- (AC) and automated and edited (AEC) contouring methods. In the AEC group, created contours (prostate, seminal vesicles, bladder, rectum, femoral heads and penile bulb) were edited, whereas the MC group included empty datasets for MC. In one clinic, lymph node CTV delineations were evaluated for interobserver variability. Compared to MC, the mean time saved using the AST was 12 min for the whole data set (46%) and 12 min for the lymph node CTV (60%), respectively. The delineation consistency between MC and AEC groups according to the Dice similarity coefficient (DSC) improved from 0.78 to 0.94 for the whole data set and from 0.76 to 0.91 for the lymph nodes. The mean DSCs between MC and AC for all six clinics were 0.82 for prostate, 0.72 for seminal vesicles, 0.93 for bladder, 0.84 for rectum, 0.69 for femoral heads and 0.51 for penile bulb. This study proves that using a general DL-based AST for CT images saves time and improves consistency.
- 17 November 2020
- Published by MDPI AG in Diagnostics
- Vol. 10 (11) , 959
Open AccessA Deep Learning-Based Automated CT Segmentation of Prostate Cancer Anatomy for Radiation Therapy Planning-A Retrospective Multicenter Study
A commercial deep learning (DL)-based automated segmentation tool (AST) for computed tomography (CT) is evaluated for accuracy and efficiency gain within prostate cancer patients. Thirty patients from six clinics were reviewed with manual- (MC), automated- (AC) and automated and edited (AEC) contouring methods. In the AEC group, created contours (prostate, seminal vesicles, bladder, rectum, femoral heads and penile bulb) were edited, whereas the MC group included empty datasets for MC. In one clinic, lymph node CTV delineations were evaluated for interobserver variability. Compared to MC, the mean time saved using the AST was 12 min for the whole data set (46%) and 12 min for the lymph node CTV (60%), respectively. The delineation consistency between MC and AEC groups according to the Dice similarity coefficient (DSC) improved from 0.78 to 0.94 for the whole data set and from 0.76 to 0.91 for the lymph nodes. The mean DSCs between MC and AC for all six clinics were 0.82 for prostate, 0.72 for seminal vesicles, 0.93 for bladder, 0.84 for rectum, 0.69 for femoral heads and 0.51 for penile bulb. This study proves that using a general DL-based AST for CT images saves time and improves consistency.